Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma

Elena Pomari, Federica Lovisa, Elisa Carraro, Simona Primerano, Emanuele S G D'Amore, Paolo Bonvini, Luca Lo Nigro, Rita De Vito, Luciana Vinti, Piero Farruggia, Marta Pillon, Giuseppe Basso, Katia Basso, Lara Mussolin

Research output: Contribution to journalArticle


Although probability of event-free survival in pediatric lymphoblastic T-cell lymphoma (T-LBL) is about 75%, survival in relapsed patients is very poor, so the identification of new molecular markers is crucial for treatment optimization. Here, we demonstrated that the over-expression of miR-223 promotes tumor T-LBL cell growth, migration and invasion in vitro. We found out that SIK1, an anti-metastatic protein, is a direct target of miR-223 and consequently is significantly reduced in miR-223-overexpressing tumor cells. We measured miR-223 expression levels at diagnosis in tumor biopsies from 67 T-LBL pediatric patients for whom complete clinical and follow up data were available, and we found that high miR-223 expression (above the median value) is associated with worse prognosis (PFS 66% vs 94%, P=0.0036). In addition, the multivariate analysis, conducted taking into account miR-223 expression level and other molecular and clinical characteristics, showed that only high level of miR-223 is an independent factor for worse prognosis. MiR-223 represents a promising marker for treatment stratification in pediatric patients with T-LBL and we provide the first evidence of miR-223 potential role as oncomir by SIK1 repression.

Original languageEnglish
Pages (from-to)107886-107898
Number of pages13
Issue number64
Publication statusPublished - Dec 8 2017

Fingerprint Dive into the research topics of 'Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Pomari, E., Lovisa, F., Carraro, E., Primerano, S., D'Amore, E. S. G., Bonvini, P., Nigro, L. L., Vito, R. D., Vinti, L., Farruggia, P., Pillon, M., Basso, G., Basso, K., & Mussolin, L. (2017). Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget, 8(64), 107886-107898.